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ABSTRACT:
A variety of Ruthenium complexes possessing terpyridine complexes as ligands in their
coordination sphere have been investigated extensively as DNA photo nucleases in vitro(1,2).
This work has led to the realization that compounds of Ruthenium bind to DNA purines and that
the interactions are of an unprecedented bridging variety. Owing to the molar absorptivity of
these complexes in the visible region, direct cleavage of duplex DNA by these complexes
requires irradiation in the range of 400-500 nm.
Although the observation of DNA photo cleavage in vitro makes these systems good
candidates for further investigation, it does not provide any information on whether the
compounds would enter cells in vivo, cause cellular damage or death, or be able to penetrate the
nucleus to affect DNA photo cleavage. In the present study, we explore the DNA photo cleavage
using gel electrophoresis, cytotoxicity, photocytotoxicity and nuclear DNA damage by the
Ruthenium compounds, which were recently shown to possess an emissive, pH- dependent
ligand centered excited state.
INTRODUCTION:

Skin cancer is the most common form of cancer in the United States. More than 3.5 million cases
in two million people are diagnosed annually3. The incidence of many common cancers is
falling, but the incidence of melanoma continues to rise significantly, at a rate faster than that of
any of the seven most common cancers4. According to the U.S. Department of Health and
Human Services, Ultraviolet radiation is a proven carcinogenic to humans. Frequent tanners
using new high-pressure sunlamps may receive as much as 12 times the annual UVA dose
compared to the dose they receive from sun exposure5. UV light (200 – 300 nm) causes

exogenous, irreversible damage to the DNA. UV-B radiation causes cross-linking of adjacent
cytosine and thymine bases creating pyrimidine dimers. This is called direct DNA damage. UVA light results in the formation of free radicals. The damage caused by free radicals is called
indirect DNA damage.

If the doctor suspects that a spot on the skin is melanoma, the patient will need to have a biopsy.
In this procedure, the doctor tries to remove all of the suspicious-looking growth. This is an
excisional biopsy. If the growth is too large to be removed entirely, the doctor removes a sample
of the tissue. The doctor will never "shave off" or cauterize a growth that might be melanoma.
This might cause metastasis of the cancer. Some cancer cells acquire the ability to penetrate the
walls of lymphatic and/or blood vessels, after which they are able to circulate through the
bloodstream (circulating tumor cells) to other sites and tissues in the body. After the tumor cells
come to rest at another site, they re-penetrate through the vessel or walls, continue to multiply,
and eventually another clinically detectable tumor is formed. This new tumor is known as a
metastatic or secondary tumor. If the cancer spreads to other tissues and organs, it may decrease
a patient's likelihood of survival. At present, the treatments available for skin cancer are Surgery,

Chemotherapy, Biological therapy, Radiation therapy and Photodynamic therapy. Of these,
surgery and chemotherapy are conventional, painful and have a large number of side effects like
diarrhoea, anorexia, fatigue and hair loss. Biological therapy includes use of interferons,
interleukins, colony-stimulating factors, monoclonal antibodies, vaccines, gene therapy, and
nonspecific immunomodulating agents and it is associated with flu-like symptoms including
fever, chills, nausea, vomiting, appetite loss and increase in blood pressure. Radiation therapy
can cause many side effects. Some are minor and diminish after therapy is stopped. The side
effects include fatigue, skin inflammation in the treated areas, frequent or uncomfortable
urination and rectal bleeding or irritation. Some side effects, however, are permanent. Bowel
function may never become normal even after treatment is stopped. Impotence can occur up to 2
years post-treatment in some patients.

PHOTODYNAMIC THERAPY (PDT):

Photodynamic therapy (PDT) is a treatment that uses a drug, called a photosensitizer or
photosensitizing agent, and a particular type of light. When photosensitizers are exposed to a
specific wavelength of light, they produce a form of oxygen that kills nearby cells(7,8,9).Each
photosensitizer is activated by light of a specific wavelength(8,9). This wavelength determines
how far the light can travel into the body(9,10). Thus, doctors use specific photosensitizers and
wavelengths of light to treat different areas of the body with PDT. In the first step of PDT for
cancer treatment, a photosensitizing agent is injected into the bloodstream. The agent is absorbed
by cells all over the body but stays in cancer cells longer than it does in normal cells.
Approximately 24 to 72 hours after injection7, when most of the agent has left normal cells but

remains in cancer cells, the tumor is exposed to light. The photosensitizer in the tumor absorbs
the light and produces an active form of oxygen that destroys nearby cancer cells(7,8,9).

In addition to directly killing cancer cells, PDT appears to shrink or destroy tumors in two other
ways(1,7,8,9). The photosensitizer can damage blood vessels in the tumor, thereby preventing the
cancer from receiving necessary nutrients. In addition, PDT may activate the immune system to
attack the tumor cells. The light used for PDT can come from a laser or light-emitting diodes
(LEDs). Photosensitizers tend to build up in tumors and the activating light is focused on the
tumor. As a result, damage to healthy tissue is minimal. However, PDT can cause burns,
swelling, pain, and scarring in nearby healthy tissue9. Other side effects of PDT are related to the
area that is treated. They can include coughing, trouble swallowing, stomach pain, painful
breathing, or shortness of breath but these side effects are usually temporary.

DNA PHOTONUCLEASES:

DNA photonucleases or Photosensitizers (PS) are one of the key elements in PDT. After the
approval of Photofrin® for PDT treatment, researchers from all over the world became actively
involved in developing efficient compounds that can be used as photosensitizers. An ideal PS
should fulfill the following requirements –

a) It should be able to produce singlet oxygen efficiently because singlet oxygen and
Norrish type II photochemical reaction is responsible for the majority of lesions
generated during PDT.
b) It should have high absorption coefficient.
c) It should have no dark toxicity, minimal or absent skin photosensitivity, and should
selectively accumulate in tumor tissue, in order to minimize skin sensitivity.
d) The distribution of PS is important in PDT processes and is influenced by its chemical
structure. It is particularly useful if PS is amphiphilic, which should facilitate the crossing
of cell membranes.
e) It should be stable and easy to dissolve in the injectable solvents. However, after
administration, the compounds should show high tumor accumulation and rapid clearance
from the system.
f) It should be chemically pure and can be obtained in a short and high yielding synthetic
route.

Unfortunately, till date, no PS with all these ideal characteristics has been developed.

The DNA photonucleases get excited by light of a specific wavelength. This excitation
uses either visible or near-infrared light. In photodynamic therapy, either the photo
sensitizer molecule or the metabolic precursor of one is administered to the patient. The
tissue to be treated is exposed to light suitable for exciting the photo sensitizer. Usually,
the photo sensitizer is excited from a ground triplet state to an excited singlet state. It then
undergoes intersystem crossing to a longer-lived excited triplet state. One of the few
chemical species present in tissue with a ground triplet state is molecular oxygen. When
the photo sensitizer and an oxygen molecule are in proximity, an energy transfer can take
place that allows the photo sensitizer to relax to its ground singlet state, and create an
excited singlet state oxygen molecule. The ROS, generated in PDT, damage the
biomolecules, such as proteins and lipids, generating photoproducts. The mechanisms of

ROS production can be type I, type II or both. The superoxide and other radicals species
are generated with the type I mechanism by electron transfer from photo sensitizer, in the
excited triplet state (T1), to ground-state oxygen (3O2). Singlet oxygen is generated with
the type II mechanism by energy transfer from photo sensitizer T1 to 3O2(12,13).

Type I radical mechanisms may work to a limited extent in the absence of oxygen based
on the oxygen independent photosensitized cross-linking of DNA. However, this does not
lead to cell photoinactivation11. Singlet oxygen is a very aggressive chemical species and
will very rapidly react with any nearby biomolecules. Ultimately, these destructive
reactions will kill cells through apoptosis or necrosis.

MECHANISM OF CELL APOPTOSIS:

The lifetime of photo sensitizer molecule in the triplet state in tissues is about 10µs11,
which is long enough or the triplet state oxygen to form singlet oxygen, therefore is
dependent on the oxygen concentration. It is therefore, realized that the oxygen
dependency of PDT in cells is a crucial factor. Most normal tissues contain about 5%
oxygen, which is supplied by blood circulation. The reason why they contain less than
20% is simply respiration. But, the skin cells are often inflamed, well vascularized, and
have slightly higher temperatures. Hence, the photo sensitizers has good selectivity for
skin cancer cells11. PDT is unique in its ability to induce extensive apoptosis of a cancer
cell. PDT causes acute inflammation, expression of heat-shock proteins, invasion and
infiltration of the tumor by leukocytes, and might increase the presentation of tumorderived antigens to T cells. The hallmarks of apoptosis in animal cells include chromatin
condensation, inter-nucleosomal DNA cleavage, cell fragmentation, and formation of
apoptotic bodies. These bodies are removed by scavenging macrophages14. DNA

fragmentation in particular has been used as an indication of apoptosis, and several
simple assays have been used to assess the extent of DNA fragmentation in apoptotic
cells. For example, agarose gel electrophoresis15 is used to demonstrate the ladder pattern
of DNA which is generated by endonucleolytic cleavage of genomic DNA into
nucleosomal size DNA of approximately 180 bases long (monomers) or oligonucleotides,
which are multiples of 180 bases (oligomers)16.

TYPES OF INORGANIC PHOTOSENSITIZERS BEING TESTED:
Various metal compounds have been tested as possible photosensitizers for PDT17. Some of them
are –

A) Transition metal complexes: Metal complexes can act as prospective photosensitizers
through both energy and electron transfer to oxygen molecules. Most of the studies on
photogeneration of singlet oxygen involve polypyrrolic dyes and their metalloderivatives,
but there is a significant number of other metal complexes capable of photosensitized
singlet oxygen generation. A low energy triplet excited state of long lifetime is a
prerequisite for this phenomenon. Mono and dinuclear RuII, CrIII, OsII, IrIII and PdII
complexes with polypyridines, can be used as singlet oxygen photogenerators.
B) Macrocyclic Photosensitizers modified by metal ions: Insertion of a metal ion to a
polypyrrolic photo sensitizer can modify properties of its ground and excited state in such
a way that not only photophysical and spectroscopic properties of the photo sensitizer
will be modulated, but also its hydrophobicity, degree of aggregation, stability and
consequently the route of the photo sensitizer transport into the cell and its further
distribution.

C) Semicondutors: Redox properties of excited semiconductor particles, especially TiO2 are
responsible for high efficiency of ROS generation. TiO2 itself shows a very weak or no
toxicity in vitro and in vivo. A significant cytotoxicity of TiO2 particles irradiated with
UV light has been reported in the context of PDT applications.
RUTHENIUM COMPLEXES AS PHOTOSENSITIZERS17:

The drastic growth in research and development of DNA photonucleases based on Ruthenium
complexes has been seen over the last decade. Various strategies have been used to improve the
sequence selectivity of cleavage, which can arise from the preferential binding or activity at a
certain site. Several mechanisms can be engaged in photoactivated DNA cleavage by Ruthenium
complexes:

a) Oxidation of the base by singlet oxygen formed via energy transfer from the triplet
excited state of the photocleaver
b) Direct electron transfer from the base to the excited state of the photocleaver
c) Oxidation of the base by RuIII complex formed in situ by oxidative quenching of the
triplet excited state of the corresponding complex

There are three main properties that make ruthenium compounds well suited to target the cancer
cells:
(i) rate of ligand exchange
(ii) the range of accessible oxidation states and
(iii) the ability of ruthenium to mimic iron in binding to certain biological molecules.

(i) Ligand Exchange18
Many ruthenium complexes have been evaluated for clinical applications, particularly in the
treatment of cancer, due in part, to Ru(II) and Ru(I1I) complexes having similar ligand exchange
kinetics to those of Pt(II) complexes. Ligand exchange is an important determinant of biological
activity, as very few metal drugs reach the biological target without being modified. Most
undergo interactions with macromolecules, such as proteins, or small S-donor compounds and/or
water. Some interactions are essential for inducing the desired therapeutic properties of the
complexes. As the rate of ligand exchange is dependent on the concentration of the exchanging
ligands in the surrounding solution, diseases that alter these concentrations in cells or in the
surrounding tissues can have an effect on the activity of the drug.

(ii) Oxidation State18
Ruthenium is unique amongst the platinum group in that the oxidation states Ru(Il), Ru(III)
and Ru (IV) are all accessible under physiological conditions. In these oxidation states the
ruthenium centre is predominantly hexacoordinate with essentially octahedral geometry, and Ru
(III) complexes tend to be more biologically inert than related Ru(II) and (IV) complexes. The
redox potential of a complex can be modified by varying the ligands. In biological systems
glutathione, ascorbate and single electron transfer proteins are able to reduce Ru(III) and Ru(IV),
while molecular oxygen and cytochrome oxidase readily oxidize Ru(II). The redox potential of
ruthenium compounds can be exploited to improve the effectiveness of drugs in the clinic.
Cancer cells are known to have higher levels of glutathione and a lower pH than healthy tissues,
creating a strongly reducing environment. If the active Ru(II) complex leaves the low oxygen
environment, it may be converted back to Ru(III) by a variety of biological oxidants. Proteins

that can catalyse the reduction of Ru(III) to Ru(II) include mitochondrial and microsomal single
electron transfer proteins. The mitochondrial proteins are of particular interest in drug design as
apoptosis, the desired mechanism for cell death, can be initiated in the mitochondria, as well as
by other pathways, for instance, by the Fas/FasL pathway. Transmembrane electron transport
systems can also reduce Ru(III) complexes outside of the cell and this is highly relevant to the
mechanism of action of a ruthenium based drug in clinical use which has anticancer activity
independent of cell entry.

(iii) Iron Mimicking
The low toxicity of ruthenium drugs is also believed to be due to the ability of ruthenium to
mimic iron in binding to many biomolecules, including serum transferrin and albumin. These
two proteins are used by mammals to solubilise and transport iron, thereby reducing its toxicity.

Since rapidly dividing cells, for example microbially infected cells or cancer cells, have a greater
requirement for iron, they increase the number of transferrin receptors located on their cell
surfaces, thereby sequestering more of the circulating metal loaded transferrin. As a result,
ruthenium drugs bind more selectively to the cancer cells and hence are less toxic to the
surrounding normal cells.

PHOTOCHEMISTRY OF RUTHENIUM COMPOUNDS19,20:

Ruthenium compounds have been selected as photosensitizers because of their unique
combination of chemical stability, redox properties, excited state reactivity, luminescence
emission and excited state lifetime. Ru2+ is a d6 system and the polypyridine ligands are usually
colourless molecules possessing the σ donor orbitals localized on the nitrogen atoms and π donor
and π* acceptor orbitals more or less delocalized on aromatic rings. This opens up a range of new
transitions, aside from the HOMO-LUMO transition observed in organic chromophores. This
transition in inorganic photochemistry is called a ligand-field or ligand-ligand transition, as the
excited state electron is located on the ligand. Apart from this, because of the presence of the
metal’s molecular orbitals, 3 other transitions are available:

a) d-d transition, where an electron is excited from a metal orbital to an unoccupied metal
orbital. This is usually referred to as a metal centred (MC) transition
b) Transitions between the metal and the ligand. These can be either an electron excited
from the ligand to the metal, called Ligand to Metal Charge Transfer (LMCT) or from the
metal to the ligand (MLCT).
c) Ligand – ligand transitions

Because of the energy differences between the various types of transitions, ligand field
transitions are usually in the near-UV region, charge transfer transitions are in the visible region.
The resulting emission from charge-transfer states is often highly coloured.

Ruthenium in oxidation state II is d6, and so as an octahedral complex its electrons are in the
low-spin t2g6 configuration. Incident light at about 450 nm promotes one of these electrons to a
ligand anti-bonding orbital, a metal to ligand charge transfer. Therefore, the S0 – S1 notation used
in the Jablonski diagrams for excited state of Ruthenium compounds can be represented as
1

MLCT. Transfer to 3MLCT is efficient and so ruthenium complex’s photochemistry generally

happens from here. From the Jablosnki diagram21, we can note that promotion of an electron
from πM metal orbital to πL* ligand orbitals gives rise to metal to ligand charge transfer (MLCT)
excited states whereas promotion of an electron from πM to σM* orbitals gives rise to metal
centered (MC) excited states. Ligand centered (LC) excited states can be obtained by promoting
an electron from πL to πL*.

DNA BINDING:

Deoxyribonucleic acid, DNA, is a molecule of great biological significance. The total DNA
content of a cell is termed the ‘Genome’. The ‘Genome’ is unique to an organism, and is the
information bank governing all life processes of the organism, DNA being the form in which this
information is stored. Stretches of DNA called ‘genes’ have the extremely important function of
coding for proteins. DNA is present in the body in the form of a double helix, where each strand
is composed of a combination of four nucleotides, adenine (A), thymine (T), guanine (G) and
cytosine (C) 22. The structure of DNA does not only exist as secondary structures such as double
helices, but it can fold up on itself to form tertiary structures by supercoiling. Supercoiling
allows for the compact packing of circular DNA. Circular DNA still exists as a double helix, but
is considered a closed molecule because it is connected in a circular form. A superhelix is
formed when the double helix is further coiled around an axis and crosses itself. Supercoiling not

only allows for a compact form of DNA, but the extent of coiling also affects the DNA’s
interactions with other molecules by determining the ability of the double helix to unwind.

Supercoiling changes the shape of DNA. The benefit of a supercoiled DNA molecule is its
compatibility. A nick is a discontinuity in a double stranded DNA molecule where there is no
phosphodiester bond between adjacent nucleotides of one strand typically through damage or
enzyme action. In comparison to a relaxed DNA molecule of the same length, a supercoiled
DNA is more compact. This is reflected in experimentation as the supercoiled DNA moves faster
than relaxed DNA. Therefore, the structural differences can be analyzed in techniques such as
electrophoresis and centrifugation.
DNA starts transcribing or replicating only when it receives a signal, which is often in the form
of a regulatory protein binding to a particular region of the DNA. Thus, if the binding specificity
and strength of this regulatory protein can be mimicked by a small molecule, then DNA function
can be artificially modulated, inhibited or activated by binding this molecule instead of the
protein. Thus, this synthetic/natural small molecule can act as a drug when activation or

inhibition of DNA function is required to cure or control a disease. DNA inhibition would
restrict protein synthesis, or replication, and could induce cell death. Though both these actions
are possible, mostly DNA is targeted in an inhibitory mode, to destroy cells for antitumor and
antibiotic action.
Drugs bind to DNA both covalently as well as non-covalently. Covalent binding in DNA is
irreversible and invariably leads to complete inhibition of DNA processes and subsequent cell
death. Non-covalently bound drugs mostly fall under the following two classes:
1. Minor groove binders- Minor groove binding drugs are usually crescent shaped, which
complements the shape of the groove and facilitates binding by promoting Van der Waals
interactions. Additionally, these drugs can form hydrogen bonds to bases, typically to N of
adenine and O of thymine. Most minor groove binding drugs bind to A/T rich sequences.
2. Intercalators- These contain planar heterocyclic groups which stack between adjacent DNA
base pairs. The complex, among other factors, is thought to be stabilized by π-π stacking
interactions between the drug and DNA bases. Intercalators introduce strong structural
perturbations in DNA.
AGAROSE GEL ELECTROPHORESIS:

Agarose gel electrophoresis is the method used to acknowledge the damage done by the
compound to the DNA. Nucleic acid molecules are separated by applying an electric field to
move the negatively charged molecules through an agarose matrix. Shorter molecules move
faster and migrate farther than longer ones because shorter molecules migrate more easily
through the pores of the gel. This phenomenon is called sieving23. The most important factor is
the length of the DNA molecule, smaller molecules travel faster. In this case, the supercoiled

DNA moves faster than the nicked DNA due to its compact size and hence moves faster and to a
longer distance. Increasing the agarose concentration of a gel reduces the migration speed and
enables separation of smaller DNA molecules. The higher the voltage, the faster the DNA
moves. But voltage is limited by the fact that it heats and ultimately causes the gel to melt. High
voltages also decrease the resolution. The most common dye used to make DNA or RNA bands
visible for agarose gel electrophoresis is ethidium bromide. It fluoresces under UV light when
intercalated into DNA (or RNA). By running DNA through an EtBr-treated gel and visualizing it
with UV light, any band containing more than ~20 ng DNA becomes distinctly visible. EtBr is a
known mutagen, however, so safer alternatives are available.

EXPERIMENTAL SECTION:

The metal complexes under study should be nontoxic in the dark, absorb in the phototherapeutic
window (600-1000 nm), have good DNA binding ability, able to cause photo-destruction of the
cell. Ruthenium complexes are developed to imitate the action of cisplatin and show better
activity, particularly on secondary tumors, and to reduce the host toxicity at active doses. In this
research, we have tested the possibility of 3 ruthenium complexes showing good photodynamic
activity. The 3 compounds tested were:

a) Ru (tpy) (Br-pic) (dmso) (PF6)
b) Ru (tpy) (mal) (dmso)
c) Ru (tpy) (bpy) (CH3CN) (OTf)2
Where, bpy- 2,2’- bipyridine
tpy- 2,2’,6,2’’- terpyridine

Otf- trifluoromethylsulfonate

Br-pic- 6- bromopicolinate

mal- malonate

These 3 compounds were tested for photophysical, photochemical and photobiological activity in
order to understand their photo anti-cancer activity.

A) SPECTROSCOPIC STUDIES:

1) UV-VIS studies- All the three complexes under study are colored. It is evident that, they
absorb in the visible region. UV-Visible absorption studies were performed on the
solution of complexes in DMSO using ocean optics spectrophotometer. The results of
wavelength maxima and molar extinction co-efficient were noted.
2) Fluorescence studies: We performed the fluorescence studies using Ocean optics
instrument USB 2000 for each compound. We did not observe any fluorescence in these
compounds.

B) DNA BINDING STUDIES:
DNA binding constant (Kb) is a proportionate measure of the binding ability of the complex
with the DNA. Binding constant, Kb is measured by the optical titration method as both the
complexes tested are showing an increasing hypochromicity as calf thymus DNA is
added24.Binding constant, Kb, is determined from the absorption changes during the DNA
titration using the equation given below:

(

a-

b)/(

b-

f)

= (1/ Kb) x ( 1/[DNA]) + 1

ɛa = molar extinction coefficients for the absorption values at a given DNA concentration.
ɛb = molar extinction coefficient for the absorption value of the complex fully bound to
DNA.
ɛf = molar extinction coefficient for the absorption value of the complex free in solution

The absorption and ɛb of the bound complexes was determined from the titration where
further addition of DNA did not result in changes to the spectrum. The binding constant for
each molecule was determined by plotting (ɛa-ɛb)/(ɛb-ɛf) vs 1/[DNA], and Kb can be
calculated as the reciprocal value of the slope.

C) DNA PHOTOCLEAVAGE STUDIES:

Gel electrophoresis is a technique used to separate the DNA fragments based on their size.
First, the gel is prepared. Gels are made of Agarose, a sea weed extract similar to gelatin. The
finished gel has a consistent appearance. This consistency offers resistance to the pieces of
DNA as they try to move through the gel. Once the DNA samples are loaded onto the gel, an
electric current is applied to the gel. The gel electrophoresis is based on the fact that the
supercoiled DNA (uncut plasmid) will travel more rapidly than nicked DNA. DNA is
negatively charged due to the phosphate back bone. Thus DNA will move towards the
positive electrode.
1.5% Agarose gel was prepared by dissolving 0.75 g of Agarose in 50 ml of 2.5 X TrisEDTA buffer, with the application of heat using a hot plate and a magnetic stirrer until the
morbid solution became clear. Ethidium bromide was added to the lukewarm solution in
order to minimise the vapours of ethidium bromide. Ethidium bromide is mutagenic and
should be handled with extreme care. The DNA is visualised in the gel by the addition of
ethidium bromide, which strongly binds to the DNA by intercalating between the bases
.Buffers not only prevent ionic changes in the surroundings, but also provide ions to support
conductivity. The use of high concentration of buffers (10X), may result in the melting of the
gel due to the heat generated. Slowly, the gel solution was poured into the gel plate without

any air bubbles. Pouring the gel solution slowly into the gel plate reduces the air bubbles in
the gel. Insert the gel comb at one end. It can be left to solidify for 15-20 minutes.
The gel plate is then placed in the gel box, containing the buffer, and is connected to the
power supply. Slowly remove the comb, so that the wells formed are well resolved. Samples
are prepared by adding 5µl of plamid, 5µl of the complex and 2µl of the loading dye
(bromophenol blue). Loading dye provides the density required for the sample to be easily
loaded in to the well. Loading dyes are negatively charged in the neutral buffers and thus
move in the same direction as the DNA, allowing us to monitor the progress of the gel.
Bromophenol blue migrates at a rate equivalent to 200-400 base pair DNA. So, to look at
fragments near this size ( ie., anything smaller than 600 bp), a different dye has to be used.
Samples are then loaded in to the wells. The lid of the gel box is closed and voltage is
applied. Stop the current supply when the loading dye has run ¾ the length of the gel. Carry
the gel to a dark room to look under the UV light, which is carcinogenic. So, protective
glasses, gloves and long sleeves should be used to avoid the contact of UV light with the
skin.
D) SINGLET OXYGEN STUDIES11:
Singlet oxygen is the only electronically excited state of molecular oxygen. Used
intentionally as a deleterious species in photodynamic therapy, its role as a biological
messenger is being increasingly recognized.1O2 is mainly a product of photochemical
reactions and its synthesis is eukaryotes is very limited confined to specific type of cells like
eosinophils and macrophages. It exists in excited state for only a short time before losing its
reactivity by transferring excess energy to other molecules or by returning to ground state.

There are no anti-oxidant enzymes for elimination of singlet oxygen and chemical scavengers
that intercept this oxygen metabolite must be present at high concentrations to be effective.
The lifetime of 1O2 in water, which is only up to 4µs, limits the distance it can diffuse in cells
and therefore, restricts its reactivity to the so-called “spatially resolved” reactions29. It readily
reacts with DNA, lipids and proteins. Among amino acids residues, the most reactive with
singlet oxygen are histidine, tryptophan,methionine, cysteine and tyrosine which form short
lived endo- or hydroxy peroxides. In the presence of redox-reactive metal ions, these
peroxides undergo decomposition with the formation of reactive radicals that can propagate
chain reactions and oxidative damage to other biomolecules30,31. In the presence of Fe2+ or
Cu2+, lipid peroxides can participate in Fenton reactions to produce oxy- (LO) and peroxy(LOO) radicals capable of inducing DNA damage.
Methods for 1O2 detection include EPR spectroscopy using spin traps32, phosphorescence at
1270 nm33 and chemical trapping34. The current spread of fluorescence imaging techniques
has lead to the development of a number of 1O2 fluorescent probes, such as trans-1-(2 methoxyvinyl)pyrene (MVP)35, dansyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrole
(DanePy)36,or fluorescein-based probes such as DMAX or DPAX37. Invitrogen/Molecular
Probes has recently marketed a highly selective sensor for 1O2 without any appreciable
response to hydroxyl radicals or superoxide, under the trade name Singlet Oxygen Sensor
Green (SOSG) reagent®38. While the exact structure of SOSG has not been disclosed, its
absorption spectrum resembles that of DMAX and it may therefore be assumed to contain a
fluorescein bound to a dimethylanthracene derivative.

The Singlet Oxygen Sensor Green reagent38 is highly selective for 1O2. Unlike other available
fluorescent and chemiluminescent singlet oxygen detection reagents, it does not show any
appreciable response to hydroxyl radical (.OH) or superoxide (.O2). This new singlet oxygen
indicator initially exhibits weak blue fluorescence, with excitation peaks at 372 and 393 nm
and emission peaks at 395 and 416 nm. In the presence of singlet oxygen, it emits a green
fluorescence similar to that of fluorescein (excitation/emission maxima ~504/525 nm). The
Singlet Oxygen Sensor Green reagent is supplied as a cell impermeant derivative.
Coming to the method, 100 µg vial in 330 µL of methanol was used to make a stock solution
of ~500 uM which produced green fluorescence at 525 nm. Then, compound solutions were
irradiated for their time of irradiation respectively, then 40 uL of sensor green (10 uM) was
added and immediately a fluorescent reading was taken. The fluorescent reading of only
sensor green (no compound) and only compound without irradiation with sensor green were
also taken to compare the results.

E) CELL STUDIES:

The human skin fibroblast cells obtained from the ATCC are cultured in 600 ml culture
flasks using DMEM. The media is previously inoculated with Amphotericin B and
Gentamycin. Media is changed at regular intervals (24,48,72 hours) until the cells are fully
grown. Once the cells have fully grown, they are replated. The media is drained off. The
flasks are washed with PBS, at least thrice. Trypsin is added to the flasks, which suspends the
cells struck to the walls of the flask. The flask are tapped and placed in the incubator for not
more than 1 minute, as trypsin can digest the cells if placed in contact with them for a long
time. To ensure that most of the cells remain suspended, observe under the microscope. The

media is added immediately to inactivate the trypsin. The cells are then transferred to 60mm2
petri dishes and allowed to grow until the plate is full.

After the cells are fully grown in the petri dishes, they are transferred into 24 well plates and
then, different concentrations of the drug are added. Two such plates are made for each
compound tested – Dark and Light. One plate is not exposed to any light and immediately
placed in the incubator after wrapping with sterilized aluminium foil which is labelled as
Dark. The other plate is irradiated for a definite period of time for the drug to be
photoactivated and hence show the activity; this plate is labelled as Light. Both the plates are
incubated for 24 hrs and then the cell growth is observed. The cell growth in the wells is
quantified by BCA protein assay.
F) BCA PROTEIN ASSAY25,26,27:

The Pierce BCA protein assay is a detergent compatible formulation based on bicinchoninic
acid (BCA) for the colorimetric detection and quantitation of total protein. This method
combines the well known reduction of Cu2+ to Cu1+ by protein in ana alkaline medium with
the highly sensitive and selective colorimetric detection of the cuprous cation using a unique
reagent containing bicinchoninic acid25. The purple colored reaction product of this assay is
formed by the chelation of two molecules of BCA with one cuprous ion. This water soluble
complex exhibits a strong absorbance at 562 nm that is nearly linear with increasing protein
concentrations over broad working range (20-2000 µg/ml). The BCA method is not a true
end-point method, i.e, the final color continues to develop. However, following incubation,
the rate of continued color development is sufficiently slow to allow large numbers of
samples to be assayed together.

The macromolecular structure o protein, the number of peptide bonds and the presence o four
particular amino acids (cysteine, cystine, tryptophan and tyrosine) are reported to be
responsible for color formation with BCA28.Coming to the procedure for BCA protein assay,
the cells are incubated for 24 hrs are they are exposed to the drug. Then the media is drained
off and the cells are washed with PBS (twice). 100µl of surfactant (Tween 80) is added to
each well, and incubated for 15 to 30 minutes. The cells are destructed by the surfactant.
Then, BCA (bicinchoninic acid) assay reagent is added to each well and incubated (30
minutes-1 hour), and then the absorbance reading can be noted using a plate reader at 562
nm.

RESULTS AND DISCUSSION

A) SPECTROSCOPIC STUDIES:

When UV- Visible studies were performed using the 75µM concentration of the 3 compounds,
following results were obtained:

S.NO

3)

λmax in nm

Compound

Molar absorptivity coefficient ( ε ) in M-1cm-1

1)

Ru (tpy) (Br-pic) (dmso) (PF6)

446

3529

2)

Ru (tpy) (mal) (dmso)

502

5134

Ru (tpy) (bpy) (CH3CN) (OTf)2

455

10414

From the above data, it can be elucidated that all the three compounds likely absorb light in the
visible region. Molar extinction coefficient,

, is the measure of how strongly a chemical

absorbs particular wavelength of light. We can also observe that molar absorptivity co-efficient
has considerably increased with the increase in the number of organic ligands. In case of
compound 3, the solvent intended was CH3CN which showed an ε of 10,200 M-1cm-1. But,
owing to the systemic toxicity of CH3CN, dmso was used as the solvent and the ε was slightly
increased to 10414 M-1cm-1. Compounds 1, 2 and 3 show maximum absorbance at a wavelength
of 446, 502 and 455 nm respectively. The compounds have to be irradiated at that particular
wavelength to observe their photodynamic activity.

B) DNA BINDING STUDIES:

Binding constant, Kb was measured by the optical titration method as all the complexes tested
were showing an increasing hypochromicity as calf thymus DNA is added.
1) Ru(tpy)(Br-pic)(dmso)(PF6) was titrated with CT-DNA of concentration 800 µM until
the absorbance became steady which meant saturation or fully bound DNA. From these
values, a graph was plotted using (ɛa-ɛb)/(ɛb-ɛf) on Y-axis and 1/[DNA] on X-axis.
The slope obtained was the value of 1/Kb which was found to be 9.4 x 10-6 and hence the
DNA binding constant for this compound is 1.06 x 105/ M.

2) Ru(tpy)(mal)(dmso) solution in DMSO was titrated with calf thymus DNA of
concentration 250 µM until the absorbance starting at 0.789 steadily decreased and
became steady at 0.715. From this data, a graph was plotted and the slope was calculated
to be 1.98 x 10-6. Therefore, the drug DNA intrinsic binding constant was found to be
5.05 x 105 /M.

3) Ru(tpy)(bpy)(CH3CN)(Otf)2 which was found to have the highest molar absorptivity coefficient among the three compounds showed better DNA binding when titrated with
800 µM concentration of CT-DNA. From the graph, the slope value was calculated to be
0.8 x 10-6 and hence the intrinsic binding constant was found to be 1.16 x 106 /M.

The results of this experiment showed that all the 3 compounds bind very tightly to the DNA
when compared to the standard ethidium bromide.

C) DNA PHOTOCLEAVAGE STUDIES
All the above results cumulatively indicate that these Ruthenium terpyridine complexes bind to
CT-DNA in the groove mode. In order to show that these complexes could cause damage to DNA
when photoactivated, agarose gel electrophoresis using pBR 322 DNA was performed using various
concentrations of the compound in both dark and photo-activated forms. Photocleavage studies using
the compound Ru(tpy)(Br-pic)(dmso)(PF6) produced the following results:
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Here, Lane 1& 2- Control dark & irradiated; Lane 3 & 4- 300µM dark & irradiated; Lane 5 & 6350µM dark & irradiated; Lane 7 & 8 – 400µM dark & irradiated. From these results, we can see
that there is defintely a decrease in the distance travelled by the DNA as the concentration of the
drug increases. This is a proof for the high DNA binding constant of the compound. Now coming
to the photocleavage results, no photocleavage was observed and this only proves the singlet

oxygen studies that this compound might not be showing any photodynamic activity or the
pathway by which it acts is not by the destruction of DNA.
When we performed the DNA photocleavage studies of Ru(tpy)(mal)(dmso) after irradiating for
1.5 hrs at 502 nm, we could observe the photocleavage as below-
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In the photograph of the gel, Lane 1& 2- Control dark & irradiated; Lane 3 & 4- 250µM dark &
irradiated; Lane 5 & 6- 300µM dark & irradiated and Lane 7 & 8 – 350µM dark & irradiated.No
DNA cleavage was observed for controls in which complex was absent (lane 1 and 2), With
increasing concentration of the Ru (II) complex (lanes 3–8), the amount of Form I (supercoiled)
of pBR322 DNA diminish gradually, whereas Form II (nicked) increases. The mechanism of the
photocleavage activity can be tested by singlet oxygen studies. From this data, we can also
observe the difference in the distance travelled as we increase the concentration and hence DNA
migration studies to prove the good intrinsic binding of the compound.

Because of its very high intrinsic binding constant, Ru(tpy)(bpy)(CH3CN)(Otf)2 was of
considerable interest. DNA cleavage was monitored by reaction of supercoiled circular pBR 322
at 455 nm after irradiating for 1 hr. The following results were obtained –
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When circular plasmid DNA was subjected to electrophoresis, relatively fast migration was
observed for the supercoiled (form I) as in Lanes 1 and 2. But, when the concentration of the
compound was gradually increased, the supercoils were relaxed to generate a slower-moving
open circular form or nicked DNA (form II). On comparing the photographs obtained for the 3
compounds tested, we can see that the size of the plasmid varies though we used the same
amount of plasmid for all the experiments. This shows that the compound has good intercalation
with DNA. The difference in the distance travelled by the bands also proves the very high
binding constant of this compound.

D) SINGLET OXYGEN STUDIES:
The formation of 1O2 has been assessed by fluorescence detection by using Singlet oxygen
sensor green (SOSG) as fluorescent probe. SOSG emits green fluorescence with an excitation
and emission maxima at 504 and 525 nm respectively. In the course of our study, we have
observed that the probe doesn’t have any fluorescence by itself even when irradiated. We already
know that none of the compounds exhibit any fluorescence. We have also observed that all the 3
compounds when added to the probe did not produce any fluorescence without irradiation.
Finally, when the mixture was irradiated, we observed the following results –
a) Ru(tpy)(Br-pic)(dmso)(PF6) did not show any fluorescence even when irradiated. This
proves that the compound might not be having photodynamic activity. If it has any
activity, it might not be due to the production of singlet oxygen.

b) Ru(tpy)(mal)(dmso) showed an intensity of 938.99 at 525nm when irradiated together
which was high compared to the readings probe (28.18) and their mixture (29.96).

c) Ru(tpy)(bpy)(CH3CN)(Otf)2 on irradiation in the presence of SOSG produced a
fluorescence intensity of 1213.

The results above show that Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 can act as
good 1O2 photosensitizers.

E) CELL STUDIES AND BCA PROTEIN ASSAY:
After the cell studies were performed, BCA protein assay was performed to quantify the cell
viability. Based on the results obtained, LC 50 value was calculated for the compounds. This
experiment was performed using Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 . The
results of BCA protein assay, plotted as a graph to calculate the LC 50 are as follows –
a) Ru(tpy)(mal)(dmso)

From the graph, LC 50 value in the dark and light were found to be 1307 µM and 848 µM
respectively. These results show that this compound is a good photo sensitizer and shows activity
when irradiated with visible light. The main mechanism behind its action as we have seen can be
attributed to the production of singlet oxygen. Compared to the concentrations we used, the
lethal concentration is very high almost 5 fold and hence can be considered to have a very good
potential. Its effect on cancer cells has to be tested to confirm its clinical use.

b) Ru(tpy)(bpy)(CH3CN)(Otf)2

As we can see, the results were convincing that this compound has good DNA photocleavage
activity at a low concentration. The LC 50 value in the dark and light were found to be 1244 µM
and 488 µM respectively. This shows that though the compound might have good DNA binding
and photocleavage activity, it might still be toxic when used clinically. The result of its effect on
cancer cells has yet to be tested.

METAL COMPLEX

LC 50 (DARK)

LC 50 (LIGHT)

Ru(tpy)(mal)(dmso)

1307 µM

848 µM

Ru(tpy)(bpy)(CH3CN)(Otf)2

1244 µM

488 µM

CONCLUSION:
Octahedral Ruthenium- terpyridine complexes were employed to improve the sequence selectivity of
cleavage which can arise from preferential binding at a certain site for treatment of cancer. All the three
compounds showed good absorbance in the visible region and good DNA binding capacity. But, only

Ru(tpy)(mal)(dmso) and Ru(tpy)(bpy)(CH3CN)(Otf)2 could be proven to be good potential
photosensitizers owing to the consistent results observed in DNA photocleavage studies, Singlet
oxygen studies and the Cell studies using Human skin Fibroblasts.

FUTURE STUDIES:
In the future, we would like to continue the research for testing the compounds on cancer cells
for cytotoxicity and photocytotoxicity.
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